Skip to content
aiqbench takeAI + Quantum

aiqbench analysis

INmune Bio and Quantum Computing Inc. are leveraging QCi's Dirac-3S quantum optimization machine to analyze biomedical datasets for identifying new therapeutic indications for their Alzheimer's treatment, XPro. This partnership marks a significant commercial milestone as the first engagement of its kind for QCi in the pharmaceutical sector, directly integrating quantum algorithms with AI to prioritize high-potential disease targets. The initiative aims to validate whether quantum methods can uncover complex biological relationships more effectively than conventional statistical or machine-learning approaches.
Sources coveringThe Quantum Insider, LessWrong, Quantum Zeitgeist, Quantum Computing Report
What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

INmune Bio and QCi Apply Quantum Optimization to XPro Research

The Quantum Insider3 min read

Insider Brief PRESS RELEASE — INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio’s investigational treatment for Alzheimer’s disease and other disease conditions. The collaboration brings together INmune Bio’s data from […]

INmune Bio and Quantum Computing Inc. are collaborating to use quantum optimization, AI and biomedical data analytics to identify potential new applications for INmune Bio’s investigational treatment XPro. The companies plan to analyze clinical and preclinical data alongside public biomedical datasets using QCi’s Dirac-3S optimization machine to identify disease indications and patient populations for further study. The collaboration will compare quantum optimization…

Excerpt shown under the publisher's RSS terms · 62 words · full text and figures are on the publisher's site

Related coverage